Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05383872 · ClinicalTrials.gov registry record · NA
Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors
A NA study, sponsored by InSightec.
- Completed
- Registry status
- NA
- Development phase
- 71
- Enrollment target
NCT05383872: Completed NA study, sponsored by InSightec.
NCT05383872 is a NA study that has completed, run by InSightec. The registered enrollment target is 71 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05383872, a NA study, has completed, sponsored by InSightec.
- COMPLETED
- Registry status
- NA
- Development phase
- 71 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 for liquid biopsy in subjects with suspected Glioblastoma brain tumors
Primary Outcome
All adverse events and/or Serious Adverse Events will be documented and reported according to CTCAE
Interventions
- DEVICE Focused Ultrasound (Exablate Model 4000)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2022-08-08 |
| Est. Completion | 2025-03-05 |
| Phase | NA |
What the finished NCT05383872 record still lists
NCT05383872 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Focused Ultrasound (Exablate Model 4000) is the first listed.
NCT05383872 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05383872 about?
NCT05383872 is a clinical study titled "Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors". The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 for liquid biopsy in subjects with suspected Glioblastoma brain tumors
What is the current status of trial NCT05383872?
This trial is currently completed. It is a NA study. The enrollment target is 71 participants. The study started on 2022-08-08. Estimated completion is 2025-03-05.
What interventions are being tested in trial NCT05383872?
The interventions under investigation include: Focused Ultrasound (Exablate Model 4000) (DEVICE).
Who is sponsoring clinical trial NCT05383872?
This trial is sponsored by InSightec, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05383872's enrollment target sits among peer trials
71 1102nd of 2000 higher than 898 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI